Full metadata record

DC Field Value Language
dc.contributor.authorJung, Myung-Ho-
dc.contributor.authorKim, Hwan-
dc.contributor.authorChoi, Won-Kyoung-
dc.contributor.authorEl-Gamal, Mohammed I.-
dc.contributor.authorPark, Jin-Hun-
dc.contributor.authorYoo, Kyung Ho-
dc.contributor.authorSim, Tae Bo-
dc.contributor.authorLee, So Ha-
dc.contributor.authorBaek, Daejin-
dc.contributor.authorHah, Jung-Mi-
dc.contributor.authorCho, Jung-Hyuck-
dc.contributor.authorOh, Chang-Hyun-
dc.date.accessioned2024-01-20T20:04:16Z-
dc.date.available2024-01-20T20:04:16Z-
dc.date.created2021-09-05-
dc.date.issued2009-12-01-
dc.identifier.issn0960-894X-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/131889-
dc.description.abstractSynthesis of a new series of diarylureas and amides having pyrrolo[2,3-d]pyrimidine scaffold is described. Their in vitro antiproliferative activities against A375 human melanoma cell line and HS 27 fibroblast cell line were tested and the effect of substituents on pyrrolo[2,3-d]pyrimidine was investigated. The newly synthesized compounds, except N-acetyl derivatives (Id, Ie, and Im), generally showed superior or similar activity against A375 to Sorafenib. Among all of these derivatives, compounds Iq and Ir having imidazole and morpholine moieties, respectively, showed the most potent antiproliferative activity against A375. (C) 2009 Published by Elsevier Ltd.-
dc.languageEnglish-
dc.publisherPergamon Press Ltd.-
dc.subjectREFRACTORY SOLID TUMORS-
dc.subjectFACTOR RECEPTOR INHIBITOR-
dc.subjectRAF KINASE-
dc.subjectSUBSTITUTED UREAS-
dc.subjectPHASE-I-
dc.subjectBAY-43-9006-
dc.subjectTHERAPY-
dc.subjectPHARMACOKINETICS-
dc.subjectINTERLEUKIN-2-
dc.subjectPATHWAY-
dc.titleSynthesis of pyrrolo[2,3-d]pyrimidine derivatives and their antiproliferative activity against melanoma cell line-
dc.typeArticle-
dc.identifier.doi10.1016/j.bmcl.2009.10.051-
dc.description.journalClass1-
dc.identifier.bibliographicCitationBioorganic & Medicinal Chemistry Letters, v.19, no.23, pp.6538 - 6543-
dc.citation.titleBioorganic & Medicinal Chemistry Letters-
dc.citation.volume19-
dc.citation.number23-
dc.citation.startPage6538-
dc.citation.endPage6543-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000271430400008-
dc.identifier.scopusid2-s2.0-71749118193-
dc.relation.journalWebOfScienceCategoryChemistry, Medicinal-
dc.relation.journalWebOfScienceCategoryChemistry, Organic-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.relation.journalResearchAreaChemistry-
dc.type.docTypeArticle-
dc.subject.keywordPlusREFRACTORY SOLID TUMORS-
dc.subject.keywordPlusFACTOR RECEPTOR INHIBITOR-
dc.subject.keywordPlusRAF KINASE-
dc.subject.keywordPlusSUBSTITUTED UREAS-
dc.subject.keywordPlusPHASE-I-
dc.subject.keywordPlusBAY-43-9006-
dc.subject.keywordPlusTHERAPY-
dc.subject.keywordPlusPHARMACOKINETICS-
dc.subject.keywordPlusINTERLEUKIN-2-
dc.subject.keywordPlusPATHWAY-
dc.subject.keywordAuthorPyrrolo[2,3-d]pyrimidine-
dc.subject.keywordAuthorA375-
dc.subject.keywordAuthorHS 27-
dc.subject.keywordAuthorAntiproliferative activity-
dc.subject.keywordAuthorMelanoma-
Appears in Collections:
KIST Article > 2009
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE